You are here

  • Home
  • Archive
  • Volume 5, Issue Suppl 1
  • S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

Article info

Article menu

Download PDFPDF

S7a – New therapeutic candidates
S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study
Free

Authors

Citation

van Vollenhoven R, Hahn B, Tsokos G, et al
S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study
Lupus Science & Medicine 2018;5:doi: 10.1136/lupus-2018-abstract.45

Publication history

  • First published March 21, 2018.
Online issue publication 
March 21, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions